Experimental drug aims to rebuild immunity against rare brain infection
NCT ID NCT04781309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a drug called NT-I7 in 12 adults with progressive multifocal leukoencephalopathy (PML), a serious brain infection that occurs in people with weakened immune systems. The goal was to see if NT-I7 could increase the number of infection-fighting white blood cells (lymphocytes) to help control the virus. Participants received up to 3 injections and were followed for 12 to 19 months with blood tests, brain scans, and spinal taps.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Rare brain infection risk under scrutiny for multiple sclerosis drug ozanimod
- Can a cancer drug wake up immune cells to beat HIV-Related infections?
- Could a common steroid prevent a deadly complication in AIDS patients?
- Could immune checkpoint drugs tame a deadly brain virus?
- Experimental drug targets deadly brain virus in small trial
- Scientists uncover how PML virus hides from immune system